Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Products under Development by Stage of Development | 8 | 1 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Products under Development by Therapy Area | 9 | 1 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Products under Development by Indication | 10 | 1 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Products under Development by Companies | 13 | 2 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Products under Development by Universities/Institutes | 15 | 2 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Therapeutics Assessment | 17 | 7 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Companies Involved in Therapeutics Development | 24 | 6 |
| F. Hoffmann-La Roche Ltd. | 24 | 1 |
| Kringle Pharma, Inc. | 25 | 1 |
| Momenta Pharmaceuticals, Inc. | 26 | 1 |
| Ohr Pharmaceutical Inc. | 27 | 1 |
| Progen Pharmaceuticals Limited | 28 | 1 |
| Ribomic Inc. | 29 | 1 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Drug Profiles | 30 | 23 |
| Biologic to Activate FGF2 for Critical Limb Ischemia Drug Profile | 30 | 1 |
| CT-400 Drug Profile | 31 | 1 |
| CT-400P Drug Profile | 32 | 1 |
| GAL-F2 Drug Profile | 33 | 1 |
| necuparanib Drug Profile | 34 | 3 |
| NK-4 Drug Profile | 37 | 2 |
| PG-545 Drug Profile | 39 | 3 |
| RBM-007 Drug Profile | 42 | 1 |
| Recombinant Protein to Inhibit FGF-2 for Cancer Drug Profile | 43 | 1 |
| squalamine lactate Drug Profile | 44 | 8 |
| TR-764 Drug Profile | 52 | 1 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Dormant Projects | 53 | 2 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Discontinued Products | 55 | 1 |
| Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF-2 or bFGF) Featured News &Press Releases | 56 | 11 |
| Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO | 56 | 1 |
| May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting | 56 | 1 |
| May 02, 2016: Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee | 57 | 1 |
| Apr 27, 2016: Ohr Pharmaceutical Announces Presentation on Squalamine Lactate at the 2016 Association for Research in Vision and Ophthalmology Conference in Seattle, WA | 58 | 1 |
| Apr 18, 2016: Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program | 58 | 1 |
| Mar 29, 2016: Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program | 59 | 1 |
| Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study | 60 | 1 |
| Nov 16, 2015: Ohr Pharmaceutical Presents New Data From OHR-102 Phase II IMPACT Study in Wet-AMD at American Academy of Ophthalmology Annual Meeting | 60 | 1 |
| Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study | 61 | 1 |
| Nov 12, 2015: Ohr Pharmaceutical Announces Submission of a Special Protocol Assessment and Upcoming Presentation on OHR-102 at American Academy of Ophthalmology | 61 | 1 |
| Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion | 62 | 1 |
| Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer | 63 | 1 |
| May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting | 64 | 1 |
| May 07, 2015: Ohr Pharmaceutical Presents Data From OHR-102 Phase II IMPACT Study in Wet-AMD at ARVO Conference | 65 | 1 |
| Apr 30, 2015: Ohr Pharmaceutical to Present at the 2015 Association for Research in Vision and Ophthalmology Conference in Denver, CO | 66 | 1 |
| Appendix | 67 | 2 |
| Methodology | 67 | 1 |
| Coverage | 67 | 1 |
| Secondary Research | 67 | 1 |
| Primary Research | 67 | 1 |
| Expert Panel Validation | 67 | 1 |
| Contact Us | 67 | 1 |
| Disclaimer | 68 | 1 |